Monitoring quantitative tumor blood volume in mouse brain under Bevacizumab by the RSST1-MRI method.
Michel Sarraf 1,2 , Flavien Caraguel 1 , Franois Berger 1 , Boudewijn Van Der Sanden 1 , and Hana Lahrech 1
CEA-CLINATEC, Grenoble, Isre, Rhne-Alpes,
Joseph University, Beyrouth, Lebanon
Blood volume fraction (BVf) and vessel permeability have
been shown to indicate anti-angiogenic therapy response
at an early stage (before changes in tumor size appear).
This study demonstrates the sensitivity of the RSST1-MRI
method to quantify BVf, to detect the vasculature
changes in U87 human glioblastoma cell (in mouse brain)
at an early stage, after treatment with Bevacizumab,
which is injected intravenously at a dose of 10 mg/kg
(Student t-test: Pvalue <0.05). RSST1 is suitable to
assess the effect of new anti-angiogenic therapies, and
help physicians to take early decisions to stop,
continue or change therapy strategies during treatment.
This abstract and the presentation materials are available to members only;
a login is required.